Instructions for Authors


ISSN: 1292-3818 (Print)

ISSN: 1765-2839 (Online)


Cover Letter
General Format of Articles
Chemical Compounds
Mandatory Data Deposition and Suggested Repositories
Suggesting Reviewers

English Editing Service

Authorship and Contribution

Conflicts of Interest
Copyright and Licensing
Editors and Journal Staff as Authors

Corrections and Retractions
Appeals and complaints

All manuscripts must be submitted via the online system, and manuscripts submitted for publication must be prepared according to the guidelines given below.  

Template in PDF: Sample.pdf.
Template in MS Word: Sample.doc.

This guideline is intended to assist authors as they prepare their manuscripts. To avoid any delay and time-consuming restructuring, Oncologie asks and encourages authors to read the guidelines before writing the manuscript.

Oncologie publishes review, research articles and other types of manuscripts. All papers must be written in English, and follow a clear, concise style. The language editors may have to check the language and grammar of your submitted manuscript, and make editorial changes if deemed necessary.

For Review Articles

Reviews normally should have 150‐300 words in the abstract, be continuous (not structured) and without reference numbers. Reviews may have different sections and sub-headings according to the subject matter. The main headings of the review should be summarized as a numbered ‘Contents’ section immediately following the ‘Abstract’.

For Case Reports

Case Reports should include a succinct introduction about the general medical condition or relevant symptoms that will be discussed in the case report; the case presentation including all of the relevant de-identified demographic and descriptive information about the patient(s), and a description of the symptoms, diagnosis, treatment, and outcome; a discussion providing context and any necessary explanation of specific treatment decisions; a conclusion briefly outlining the take-home message and the lessons learned.
Begin each component on a separate page. Number all pages (starting with the title page), tables and figures in Arabic numerals. Do not number lines.

1 Cover Letter

A submitted manuscript must be accompanied by a cover letter. The cover letter must clearly state that the manuscript is an original work with its merit, has not been previously published in whole or in part, and is not being considered for publication elsewhere. It should also include statements indicating that all authors have read the final manuscript, have approved the submission to the journal, and have accepted full responsibilities pertaining to the manuscript’s delivery and contents. If any ethical, copyright, disclosure issues come with the manuscript, please reveal them in the cover letter. In the cover letter, the authors need to declare that there is no conflict of interest or disclose all the conflicts of interest regarding the manuscript submitted.

2 Templates

Authors are encouraged to use the Microsoft Word (see link above).

3 General Format of Articles

3.1 General Style

  • The paper size is US Letter (8.5“ × 11” or 21.59 cm × 27.94 cm) All margins — top, bottom, left, and right — are set to 1” (2.54 cm).

  • Use Times New Roman 11-point size for the main body of the paper, single spacing, except for the heading as outlined in Section 3.4.

  • The paper must be in a single column format.

  • Use British English or American English spellings throughout your manuscript, but not both.

  • Use 2-character indentation on the first line of each new paragraph.

  • Do not use page breaks or multiple returns between Sections.

  • Do not insert page numbers or line numbers.

3.2 Manuscripts

3.2.1 Title and Author Information

  • The title and author information should use Minion Pro font.

  • The title should be in bold, 14-point, left align of the page. Use capital letter on each word of the title.

  • Provide full names of all authors and their affiliations. The author line should be Minion Pro, 11-point and left aligned.

  • Authors should be numbered regard to their affiliations. There should be no space between the author name and the number.

  • Affiliation lines should be Minion Pro font, 9-point.

  • Corresponding author should be marked *.

3.2.2 Abstract

  • The font of the Abstract should be in 10-point size, Minion Pro.

  • Abstract of a research paper should be 200–400 words, and 150–300 words for review paper.

  • Abstract should be left aligned.

  • The abstract should be in one continuous paragraph without reference numbers.

  • All abbreviations should be defined in full unless the abbreviation appears more than once in the abstract.

3.2.3 Keywords

  • Keywords should be in the same section with the abstract, and use 10-point size, Minion Pro font.

  • Three keywords are the minimum. Use a comma to divide each keyword.

  • Keywords should be left aligned.

  • Each keyword except the first one should be lowercase unless an uppercase letter is necessary.

3.3 Headings

In the main body of the paper, three different levels of headings (for sections, subsections, and sub-subsections) may be used.

  • The section of abstract should not be numbered. Subsequent sections should be numbered consecutively in Arabic numbers, starting from 1.

  • Level one headings for sections should be in bold, and be flushed to the left, e.g., 1, 2, …

  • Level two headings for subsections should be bold-italic, and be flushed to the left. Level two headings should be numbered after the level one heading, e.g., 1.1, 1.2,….

  • Level three headings should be italic; and be flushed to the left, e.g., 1.1.1, 1.1.2,

  • Use 12-pound before paragraph distance and 3-pound after paragraph distance.

  • Do not use page breaks or multiple returns between sections.

3.4 Units and Symbols

  • Units of measurement should be used concisely according to the International System of Units (SI).

  • All units should be converted to SI units whenever possible.

  • There should be a space between the unit and Arabic number: 5 mm NOT 5mm.

  • Please use Arabic number and relevant unit in the manuscript: 5 kg NOT five kilograms or 5 kilograms or five kg.

  • Do not use hyphen/dash or any connector symbol between the value and its unit: 5 kg NOT 5-kg.

  • Please clarify all units during a calculation or a mathematical relationship: 3 cm × 5 cm NOT 3 × 5 cm, 123 g± 2 g or (123±2) g NOT 123± 2 g, 70%–85% NOT 70–85%.

  • Greek letters must be inserted using the correct Greek symbol (using Times, Helvetica or Symbol font), NOT written in full, i.e., alpha: α; beta: β, (available in Times and Helvetica); and gamma: γ, etc.

  • Abbreviations

    Abbreviations should be defined in parentheses the first time they appear in the abstract, main text, and in figure or table caption and used consistently thereafter. Accepted abbreviations for statistical parameters are: P, n, SD, SEM, df, ns, ANOVA, t. Naming of chemicals should follow that given in Chemical Abstracts Service.


    If you are using MS Word, please use either the Microsoft Equation Editor or the MathType add-on. Please submit math equations as editable text and not as images.

    Statistical Analysis

    Appropriate statistical treatment of the data is essential. When the statistical analysis is performed, the name of the statistical test used, the n number for each analysis, the comparisons of interest, the alpha level and the actual p-value for each test should be provided.

    3.5 Figures and Tables

    3.5.1 Figures

    When submitting manuscripts to ONCOLOGIE, authors must provide the original raw images of both the figures (e.g., diagrams, charts, graphs, and photographs) cited in the main text and the supporting information reported in the article. These files are required for the peer review process and must be received before a manuscript can be accepted.

    • All of the figures displayed in the text should be as simple as possible while maintaining clarity.

    • Figures should be centered and should include an explanatory caption placed underneath.

    • Each figure should be located in the text soon after its first mention in the manuscript.

    • Figures should have no frames or borders.

    3.5.2 Format for Figures

    • Figures should be in the form of either a TIFF file without layers or a JPEG file (but only if the image was originally saved as the highest possible quality JPEG).

    • Figures may be supplied as separate JPEG files if the authors are unable to include them with the text.

    • All other formats, including BMP, GIF, PCT, PNG, and low-quality JPEG files, are unacceptable.

    • Figures should be neither stretched nor distorted but in their original dimensions.

    • Photoshsop, Powerpoint, MS Word, or similar software should not be used to export or alter the color or appearance of figures.

    3.5.3 Dimensions of Figures

    • Images and figures are measured in centimeters or inches. Figures should measure 17 cm (6.70 in) wide by 20 cm (7.87 in) high.

    • Any excess white space surrounding a figure should be removed before calculating its size.

    • If a figure is wider than 17 cm (6.70 in), it should be divided into two or more separate and clearly labeled parts.

    3.5.4 Quality of Images

    • Images must be clear, high-contrast, and clearly legible at the size in which they are to appear in the journal.

    • The resolution of images should be at least 300 dpi.

    • Any low-resolution figures must be re-created from scratch.

    3.5.5 Multi-Panel Figures

    Each panel of a multi-panel figure (referred to as, e.g., Figs. 1A, 1B, 1C, and 1D in the text) should be logically connected to the other panels, and all of the panels should be assembled into a single file on a single page. Images that contain large amounts of information should be broken down into multiple figures to ensure that all of the information is visible. To repeat, multiple panels must be assembled and submitted as a single file rather than as separate files.

    3.5.6 Color Mode

    RGB (8 bit/channel), CMYK, or greyscale mode are acceptable.

    3.5.7 Labels for Figures

    • The font size for labels should be at least 8-point and no larger than the font size of the main text.

    • All labels should be in black font.

    • Figure labels must be proportionate to the image in size and sharp and legible in appearance.

    • Labels must be in standard fonts (Arial, Helvetica, or Symbol) and use the same font style and size across all of the figures in a paper.

    • Labels should not overlap or appear faded, disjointed, or distorted.

    • The letters of labels must not overlap, feature unnecessary gaps or irregular spacing, or appear condensed, expanded, or otherwise distorted either horizontally or vertically.

    • The sublabels for panels (again, referred to as, e.g., Fig. 1A, 1B, 1C, and 1D in the text) should be placed in the top left-hand corner of the panels and contrast clearly with the background. Note that each panel should be labeled with only a letter (e.g., A, B, C, and D—not 1A, 1B, 1C, and 1D).

    3.5.8 Captions for Figures

    • Figures should have explanatory captions that do not repeat information that already appears in the main text.

    • The caption should appear directly after the title of the figure to which it belongs. Any credits should appear at the end of the caption or legend.

    • Captions should not be included as part of the figure files or submitted as a separate document.

    • The captions should be numbered consecutively using Arabic numbers.

    • A one-line caption should be centered in the column, e.g., Figure 1: The text caption …

    • A caption of more than one line should be justified.

    • The first letter of each sentence must be capitalized (not each word).

    3.5.9 In-Text Citation of Figures

    • In the main text, when referring to figures, use “Fig.” or “Figs.” followed by a space and the appropriate number (e.g., “Fig. 1,” “Figs. 1A and 1B,” “Fig. 2,” “Fig. 3”).

    • Cite figures (as well as text boxes and tables) in ascending numerical order as each first appears in the manuscript. In the published article, the figures are inserted based on the placement of the first citation and caption.

    • The lettered subpanels of whole figures may be cited in any order in the text following the first mention of each whole figure in numerical order. For example, any subpart of Fig. 3 may be cited in any order (e.g., Fig. 3C before Fig. 3A) provided that Figs. 1 and 2 have already been cited.

    3.5.10 Copyright of Figures

    • If a figure or table has been published previously—even by an author of the manuscript being submitted for review—the copyright holder’s written acknowledgment and permission for its reuse are often required.

    • For any figures (or tables) that contain data from a public database (e.g., Gene Ontology/KEGG), the source should be cited in the caption, legend, or title explicitly. For publicly available DNA sequences, the accession number should be provided.

    3.5.11 Images of Gels and Blots

    • Images of gels and blots in figures should not be over cropped around the bands of interest. Rather, figure panels should include some background area above and below bands. Any non-specific bands from the original image should be included in the figure and explained in the text or figure caption or legend.

    • When a comparative analysis of bands is presented, all of the relevant samples should be run on the same gel/blot.

    • Each figure should include all of the relevant controls, and, when appropriate, control samples should be run on the same blot or gel alongside the experimental samples.

    • A figure panel should not include composite images of bands originating from multiple blots, exposures, or gels. If data from multiple blot or gel images are necessary to illustrate the results, the various images should be clearly distinguished as separate panels within the figure (not spliced together), and the caption or legend should make clear that multiple gels, blots, or exposures are being presented.

    • Any rearrangement of lanes from a single blot/gel image during the preparation of a figure as well as any image splicing should be clearly indicated with vertical black lines on the figure, and the caption or legend should explain how the figure was made. The addition of the lines would be appropriate, for example, when fragments of the same original image have been spliced together to re-order lanes or to remove irrelevant lanes.

    • Quantitative comparison of samples across multiple gels/blots is strongly discouraged. If such comparison is unavoidable, the figure legend must state whether the samples derive from the same experiment or parallel experiments and whether the gels/blots were processed in parallel. 

    • The rearrangement of lanes that are non-adjacent in a gel must be clearly indicated in a manner that delineates the boundary between the lanes and should be acknowledged in the figure caption or legend.

    • Loading controls (e.g., GAPDH, actin) must be run on the same blot. When sample processing controls are run on different gels, this fact must be acknowledged in the caption or legend. Any cropped images of gels must retain all of the important bands.

    • High-contrast gels and blots are discouraged because overexposure may mask additional bands.

    • Authors should take care to (1) check figures for duplications, (2) check blots and gels for the splicing of lanes, (3) indicate whether panels show sample processing or loading controls, and (4) ensure that the unprocessed scans provided match the figures.

    3.5.12 Figure Samples


    Song, Q., Zhang, J., Zhang, Q., Liu, J., Lv, K. et al. (2020). Exosomes derived from circBCRC-3-knockdown mesenchymal stem cells promoted macrophage polarization. BIOCELL, 44(4), 623–629.


    Figure 1: Identification of circBCRC-3 in MSCs. A. The genomic structure indicates that circular RNA BCRC-3 consists of nine exons (1,002 bp) from the PSMD1 gene. B. Agarose gel electrophoresis analysis of PCR product with divergent and convergent primers of circBCRC-3 in cDNA and gDNA. GAPDH was used as the negative control. 


    Zhang, J., Huang, Y., Liu, W., Li, L., Chen, L. (2020). Chaperone-mediated autophagy targeting chimeras (CMATAC) for the degradation of ERα in breast cancer. BIOCELL, 44(4), 591–595.


    Figure 2: The binding of peptide αI to ERα. (A) Design TAT-αI-CTM and TAT-αI peptides. (B) Production of GST and GST-TAT-αI using an E. coli expression system. Coomassie blue staining after SDS-PAGE assessed their purity. (C) Pull-down of TAT-αI and ERα. HEK 293T cells were transiently transfected with plasmids pEGFP-N2-ERα. 48 h after transfection, cell lysates were subjected to GST pull down, and the pull-down fractions were immunoblotted analyzed. (D) Pull-down of TAT-αI and ERα in ERα-positive breast cancer cell lines, MCF-7 and T47D.


    Fu, S., Yun, T., Ma, D., Zheng, B., Jiang, D. et al. (2021). Thylakoid Transit Peptide Is Related to the Expression and Localization of NdhB Subunits in Soybean. Phyton-International Journal of Experimental Botany, 90(1), 99–110.


    Figure 3: Comparisons of sizes, relative abundance of mRNA and protein, and immunolocalization for NdhB subunits in Melrose and S111-9. (A) Sizes of NdhB subunits were analyzed by SDS-PAGE. NdhB proteins were isolated and purified from the leaves of Melrose and S111-9 extracted with Crosslink IP Kit. (B) Relative mRNA expression level of ndhB in Melrose and S111-9. Bars represent the mean ± SD of three biological replicates. Student t-test was applied to assess difference of means between two varieties. Different letters indicate a significant difference between varieties (P < 0.05). (C) The content of NdhB were analyzed using western blotting in the leaves of Melrose and S111-9. The equal loading of lower pictures is shown by coomassie staining. (D) Immunolocalization of NdhB subunits in S111-9 (a,b) and Melrose (c,d). All immunogold particles were mainly concentrated in chloroplast, not in the cytosol. T, Thylakoid; S, Cytosol Stroma. Scale bars = 0.2 μm.


    Yang, Y., Xu, K., Zhao, B., Liu, N., Zhou, J. (2021). The Bacteria Absorption-based Yolk-Shell Ni3P-Carbon @ Reduced Graphene Oxides for Lithium-Ion Batteries. Journal of Renewable Materials, DOI: 10.32604/jrm.2021.014525.


    Figure 1: Schematic diagram of material synthesis process (a, b, c) and XRD pattern of the NPC @ RGO (d).

    3.5.13 Tables

    • Tables should be placed in the text after the point where they are referenced, and should be consistent with the main text.

    • Tables should be centered and should have a title placed above.

    • Table titles must be numbered consecutively using Arabic numbers.

    • One-line table title should be centered and multiple-line title should use justified alignment.

    • Use Times New Roman, font size smaller than 12 for table titles.

    • Titles should be centered in the format “Table 1: The text …”, e.g., Table. 1.

    • Table notes should be aligned with the left table frame.

    • Where reference the Tables, please use abbreviation “Table.”. followed by the number, e.g., Table. 1.

    Table 1: Table caption










    3.6 Equations and Mathematical Expressions

    3.6.1 In-line Style

    • In-line equations/expressions are embedded in paragraphs of the text. For example, E = mc2.

    • In-line equations/expressions should not be numbered.

    • In-line equations/expressions should be use as same/similar size font as the main text.

    3.6.2 Display Style

    • Equations in display format are separated from the paragraphs of text.

    • Equations should be flushed to the left margin of the column.

    • Equations should be editable.

    • Equations should be numbered consecutively using Arabic numbers. See Eq. (1) for an example. The number should be right aligned.

      E = mc2                                                                                                                                                                                                                                                                                                                                                                                                                  (1)

    3.7 In-Text Citations

    • Please cite references by number in square brackets in the main text, e.g., [1], [2], [3]…  

    • If the cited references are consecutive more than 2, please see the example, [1–3], [4–6].

    • No citation to the page number should be used.

    • Citation to the figures should be in Section 5.1. Citation to the tables should be in Section 5.3.

    3.8 References

    • All references should be in font size 10 and listed at the end of the paper  

    • References should be organized in order of citation in the main.

    • Use full name of journal cited in reference e.g., Computational Mechanics, use italic font, followed by a comma before the volume, issue and page number.

    • Keep DOI number when you have the data aforementioned.

    • Based on our particular style, the first five authors will be listed as they appear. When more than five authors are listed, keep the first five authors and followed by et al.

    • Personal communications should be avoided.

    • Non-English references should not be included in the Reference list. The entire manuscript cited must be in English.

    Reference examples:

    Reference of a book: Author Surname, Author Initial. (Year Published). Title. Publisher Location: Publisher, .

    Reference of a book chapter: Author Surname, Author Initial.(Year Published). Chapter Title. Title. Publisher Location: Publisher, .

    1. Atluri, S. N. (2004). A four-node hybrid assumed-strain finite element for laminated composite plates. USA: Tech Science Press. 

    2. Popovic-Djordjevic, J. B., Kostic, A. Z., Kiralan, M. (2021). Antioxidant activities of bioactive compounds and various extracts obtained from saffron. In: Charis, M., Galanakis (Eds.), Saffron, pp. 41–97. USA: Academic Press.

    Reference of journal article: Author Surname, Author Initial. (Year Published). Title. Journal Full Namevolume number(issue number), page number.

    1. Philip, R., Towbin, J. A., Sathanandam, S., Goldberg, J., Yohannan, T., Sawminathan, N., et al. (2019). Effect of patent ductus arteriosus on the heart in preterm infants. Oncologie, 14(1), 33–36.

    2. Willis, K. A., Weems, M. F. (2019). Hemodynamically significant patent ductus arteriosus and the development of bronchopulmonary dysplasia. Oncologie, 14(1), 27–32.

    Reference of an online source: Author Surname, Author Initial. (Year Published). Title. URL.

    Atluri, S. N. (2004). The meshless method (MLPG) for domain & BIE discretizations.

    Reference of a Thesis: Author Surname, Author Initial. (Year Published). Title (Level). Institution Name, Location.

    1. Darius, H. (2014). Savant syndrome-theories and empirical findings (Ph.D. Thesis). University of Turku, Finland.

    2. Tantawy, M. A., Soliman, M. M., Agamia, A. H., Gawish, A. Y. (2015). Evaluation of gas condensate reservoirs using production data and well test analysis–Abu Qir Fields Mediterranean SeaEgypt (Master Thesis). Faculty of Petroleum and Mining Engineering, Suez University, Egypt.

    4 Declarations

    Submitted manuscripts should, where appropriate, contain the following parts right before the list of references:

    Acknowledgments: All contributors who do not meet the criteria for authorship should be listed in this section.

    Funding Statement: Authors must disclose all sources of funding for the research in the Funding Statement of the article. The statement should be specifying the role of each in the design of the study, the collection, analysis, and interpretation of data, and the composition of the manuscript. Specifically, the full name of each source of funding should be provided accompanied by any associated grant numbers in square brackets, URLs to sponsors’ websites. If the study has no funding support, please include “The author(s) received no specific funding for this study.” in the funding statement. Funding sources should not be written in the Acknowledgments or anywhere else in the manuscript file.

    Availability of Data and Materials: This statement—which is not required for review articles—should make clear how readers can access the data used in the study and explain why any unavailable data cannot be released. 

    Conflicts of Interest: Authors must declare all potential conflicts of interest; if they have none to declare, they should state plainly, “The authors declare that they have no conflicts of interest to report regarding the present study.”

    5 Data Sharing

    Researchers share their data so that other researchers can replicate and build on their published claims. We encourage authors to share the data described and discussed in their articles. Research data can be uploaded to repositories and the access information provided in a published article or appended to the article in supplementary files. Any restrictions on the availability of research materials or information must be disclosed to the editors directly at the time of submission and in the submitted manuscript. Read more about TSP’s Data Sharing Policies.

    5.1 Reporting Requirements for Research in the Life Sciences, Behavioral and Social Sciences, and Ecology, Evolution, and Environmental Sciences

    Authors of research articles in the life sciences, behavioral and social sciences, and ecology, evolution, and environmental sciences may be required to make available details about aspects of experimental and analytical design to the editors and reviewers for the purpose of assessing the manuscript. 

    6 Chemical Compounds

    Chemical and Chemical Nomenclature and Abbreviations
    Authors should provide the exact structure of the chemical compound, and if there are appeared as new chemical compounds, authors should submit the small-molecule crystallographic data to the 
    Cambridge Structural Database (CSD) and deposit relevant information to PubChem. The final version of the manuscript should contain the accession codes. When possible, authors should use systematic nomenclature to identify chemical compounds, and biomolecules using IUPAC is preferred. Standard chemical and chemical abbreviations should be used. Chemical structures should be included as high-resolution files according to Cell Press Figure Guidelines. 

    Combinatorial Compound Libraries
    The authors should include standard characterization data for a diverse panel of library components when describing the preparation of combinatorial libraries in the manuscript.

    Chemical Structures for Organic and Organometallic Compounds
    Chemical structures for organic and organometallic compounds should be established through spectroscopic analysis. The authors should provide standard peak listings for both 1H NMR and proton-decoupled 13C NMR for all new compounds. Other NMR data, when appropriate, such as 31P NMR, 19F NMR, etc. should be reported. For the identification of functional groups, both UV and IR spectral data should be reported when appropriate. For crystalline materials, melting-point ranges should be included. For the analysis of chiral compounds, specific rotations should be reported. For known compounds, authors should provide detailed references.

    Spectral Data
    Detailed spectral data for new compounds should be provided in the Materials and methods section. The authors should explain how specific, unambiguous NMR assignments were made in the Materials and methods section.

    Crystallographic Data for Small Molecules

    For crystallographic data for small molecules, authors should provide a standard crystallographic information file (CIF) and a structural figure with probability ellipsoids. The authors should check the CIF using the International Union of Crystallography (IUCr) checkCIF. For the structure, the structure factors must be included either in the main CIF or in a separate CIF. Crystallographic data for small molecules should be submitted to the Cambridge Crystallographic Data Centre (CCDC), and the accession number must be referenced in the manuscript.     

    Biomolecular Materials
    Manuscripts reporting new biomolecular structures should contain a table summarizing structural and refinement statistics. If suitable, high-field NMR or X-ray crystallography may also be used. For new biopolymeric materials (e.g., oligosaccharides, peptides, nucleic acids, etc.), if it is not possible for structural analysis by NMR spectroscopic methods. Authors must provide evidence of the identity based on sequence (when appropriate) and mass spectral characterization.

    Biological Constructs
    Authors should provide sequencing or functional data that validates the identity of their biological constructs (plasmids, fusion proteins, site-directed mutants) upon request.


    For new materials, as well as 1H NMR and 13C NMR, the mass spectral analysis should be used to support the identification of molecular weight. Ideally, high-resolution mass spectral (HRMS) data are preferred.


    The authors must provide a detailed characterization of both individual objects and bulk composition.

    7 Mandatory Data Deposition and Suggested Repositories

    Before submission of the manuscript, the deposition of new sequence information to the community-endorsed, public repository is necessary. Accession numbers and other relevant, unique identifiers provided by the database should be included in the submitted manuscript. 

    DNA and RNA Sequences: Genbank, European Nucleotide Archive (ENA), DDBJ, Protein DataBank, UniProt 

    DNA Sequencing Data: GEO, ArrayExpress, NCBI Trace and Short-Read Archive, ENA's Sequence Read Archive

    New microarray (Data must be MIAME compliant, as described at the MGED website specifying microarray standards): Gene Expression Omnibus (GEO), ArrayExpress. Genetic polymorphisms: dbSNP, dbVAR

    Linked genotype and phenotype data: dbGAP, European Genome-phenome Archive (EGA)

    Protein sequences: UniProt (submission tool SPIN). Flow cytometry: FlowRepository

    Chemical Compound Screening and Assay Data: PubChem

    8 Suggesting Reviewers

    Authors are welcome and encouraged to suggest reviewers when they submit their manuscripts by using the submission system. Authors should make sure they are totally independent and without conflicts of interest in any way. When suggesting reviewers, the Corresponding Author must provide an institutional email address for each suggested reviewer.

    9 English Editing Service         

    Clear and concise language enables both the journal editors and reviewers to concentrate on the scientific content of your manuscript. In order to facilitate a proper peer review process and ensure that submissions are judged exclusively on academic merit, ONCOLOGIE, strongly encourages authors to prepare the language of their manuscripts with the utmost care. The use of the recommended language polishing service on your manuscript does not indicate the acceptance of your manuscript for publication in ONCOLOGIE.

    If you are an author whose native language is not English—or you have any concerns regarding the language quality of your manuscript—we recommend having your manuscript professionally edited by a qualified English-speaking researcher in your field prior to submission.

    The following is TSP's collaborating language-editing company which offering discounted services to TSP's authors. To be noticed that the use of any language-editing services does not guarantee acceptance to any TSP Journal.


    Please use the following Coupon Code to receive the special 5% off when you check out with LetPub: TSP5D

    Please use the provided link or the following Coupon Code to receive the special 10% off when you check out with Charlesworth: TSP51


    Please use the provided link to receive the special 20% off when you check out with TopEdit.

    10 Authorship and Contribution

    The listed authors include all of the individuals who have made substantial contributions to the intellectual content of an article in terms of the conception, drafting, and revising of the work and the acquisition, analysis, and interpretation of the data. Their approval is required for the submitted version as well as any substantially modified version to which they have contributed. Further, all of the listed authors are considered personally responsible for all aspects of the work and must guarantee that any questions regarding its accuracy or integrity—even for aspects of the work in which an individual author did not personally take part—are appropriately examined, resolved, and documented in the article.

    On the other hand, involvement in the securing of funding, collection of data, or general supervision of a research group does not in itself justify listing as an author. Rather, those who have contributed to the work in such ways should be listed in the acknowledgments.

    Please note that submissions by any individual other than one of the listed authors will not be considered. We expect all authors will take responsibility for the content of the manuscript they submitted. The information of contributions of all authors are urged to be described, as ONCOLOGIE may contact all authors by email to ensure the authorship.

    It is not only the edition changes that require the consent of all authors, but also the authorship changes, that is, adding and deleting authors requires the consent and signature of all authors.

    Requests made for an authorship change must include an explanation for the change and must come from the corresponding author. If the change is appropriate, the corresponding author must receive and provide the consent to the change from all the authors, including any addition or deletion. If authorship issues are found after publication, it may result in a correction. If the authors are unable to resolve the dispute of authorship by themselves, TSP may raise the issue with the authors’ institution(s) and abide by its guidelines. Please note that if you have changed affiliation during the research, your new affiliation can be acknowledged in a note. TSP does not normally take requests for changes to affiliation after the acceptance of manuscripts.

    11 Conflicts of Interest

    Conflicts of interest (COIs, also referred to as “competing interests”) may indicate the potential to influence the validity or objectivity of research. Editors, authors, and reviewers may be involved into COIs, and ONCOLOGIE considers it essential to identify and seek to mitigate them so as to ensure the integrity of its role in the dissemination and preservation of knowledge. Failure to declare competing interests may result in decline of a manuscript.

    In order to limit COIs, all roles involved in the peer-review process must identify and declare any personal circumstances or associations that may be perceived as having such influence and acknowledge all funding sources for the work. However, COI statements relating to public funding sources, such as government agencies and charitable or academic institutions, need not be supplied.

    To be specific, ONCOLOGIE defines a COI as any relationship that may have an impact on the authors, reviewers, or editors of a manuscript during the peer review process, on the making of editorial decisions, or generally on any stage in the path toward publication.

    Thus, COIs may include (but not limited to): 
    Financial COIs

    • Stock or share ownership

    • Patent applications

    • Research grants

    • Consultancies

    • Royalties

    Non-financial COIs

    • Affiliation with the same institution;

    • Personal relationships, e.g., between thesis advisers and their students, friends, family members, etc.;

    • Academic relationships, e.g., among co-authors, collaborators, or competitors;

    • Government employees;

    • Members of ONCOLOGIE editorial board of a TSP journal.

    COIs are not considered permanent; such relationships that have ended more than two years prior to the submission of a manuscript need not be identified as sources of potential conflict.


    ONCOLOGIE requires a declaration from all authors of a manuscript regarding any potential COIs that could be relevant to the integrity or reliability of the scientific and professional judgment presented therein, as well as that of otherwise unassociated studies in the same journal. Potential conflict, unless already declared, will be held in confidence while the paper is under review. If the article is accepted for publication, the potential conflict of interest will be included in the acknowledgments. If there is, in fact, no conflict of interest, the authors should state plainly.


    Reviewers should declare any COIs when they are assigned a manuscript and disclose this information to the editor, who will then assess whether they should proceed with the review process.


    Editors, including Editors-in-Chief, Associate Editors and Guest Editors should be aware of their own potential COIs. If the Editors have authored or coauthored the manuscripts submitted to ONCOLOGIE, Editors might be perceived to be influenced by the relationship. ONCOLOGIE expects the Editor(s) to declare any COIs or potential COIs.

    ONCOLOGIE publishes all articles under an open-access license, which means that the articles remain accessible to all without charge and without technical or legal barriers and that they can be reused with proper acknowledgment and citation. Financial support for the open access publication is provided by the authors’ institutions or by research funding agencies in the way of article processing charge (APC) once manuscripts have been accepted. More specifically, ONCOLOGIE publishes articles under the Creative Commons Attribution (CC BY) License. ONCOLOGIE is committed to open access publishing as a means to foster the exchange of research among scientists, especially across disciplines.

    The copyright and other proprietary rights related to papers published by ONCOLOGIE are retained by the authors. If the authors reproduce any text, figures, tables, or illustrations from the papers published by ONCOLOGIE in their own future research, they must cite the originally published version. They are further asked to inform ONCOLOGIE’s editorial office of any exceptional circumstances in this regard at the time of submission, for which exceptions may be granted at the discretion of the publisher.

    Articles published in ONCOLOGIE are likely to contain material republished with permission under a more restrictive license. When this situation arises, it should be indicated; it is the responsibility of the authors to seek permission for reuse from the copyright holder.

    13 Editors and Journal Staff as Authors

    In the circumstances where Editors or editorial staff of the journal submit their own studies to the journal, they shall not be involved in the reviewing process, and the review process must be made transparently and rigorously. Submissions authored by editors or editorial staff of the journal will be handled by another editor who has least COIs with the authors to minimize the bias.

    14 Corrections & Retractions

    TSP journals will issue corrections, and/or retraction statements, when deemed proper.


    ONCOLOGIE aims to publish every article online in its final form. Upon receiving the proofs of their accepted manuscripts, authors will have an opportunity to check for errors and oversights. Occasionally, a mistake is pointed out in a published article, necessitating the issuance of a correction statement. A correction is a statement rectifying an error or an omission, Authors or readers may submit such a statement either through the journal’s online manuscript submission system (, or by sending an email, along with the submission ID, to the ONCOLOGIE’s editorial office ( A correction notice, published and linked to the corresponding article, is freely accessible to all readers.

    When making corrections to the original articles, the original article both in PDF and XML versions are corrected and bi-directionally linked to and from the published amendment notice that details the original error. Any changes made to the original articles affect data in figures, tables or text, the amendment notice will reproduce the original data. If it is not possible to correct the original article in both PDF and XML versions, the article will remain unchanged but will contain links that direct to and from the published correction notice.

    • Author’s Correction: An Author’s Correction may be published to correct an important error(s) made by the author that affects the scientific integrity of the published article, the publication record, or the reputation of the authors or the journal. The Managing Editor of that manuscript will be responsible for handling the correction process.

    • Publisher’s Correction: A Publisher’s Correction may be published to correct an important error(s) made by the journal that affects the scientific integrity of the published article, the publication record, or the reputation of the authors or of the journal.


    A retraction is a notice that a previously published paper should no longer be regarded as part of the published literature. The primary purpose of a retraction is to ensure the integrity and completeness of scholarly records by withdrawing any manuscript which is found to contain infringements of professional ethical codes, major errors, or where its main conclusion is seriously undermined as a result of new evidence coming to light.
    Violations of professional ethical codes include multiple submissions without proper citations or permission, redundant publications, fake claims of authorship, plagiarism, fraudulent use of data, etc. Major errors cover any or all miscalculations or experimental errors, intentionally or due to honest mistakes.

    The retraction will be referred to the Editors-in-Chief, Associate Editors, and the Managing Editor who have handled the paper. Retracted articles will not be removed from the printed copies of the journal (e.g., from libraries) nor from the electronic archives. Their retracted status will be indicated as clearly as possible. Bibliographic information about the article will be retained to ensure the permanence and integrity of the published scientific record. When an article is retracted, in most of the cases, the original manuscript is corrected and is bi-directionally linked (to and from) the published retraction notice which details the original error. For the purpose of transparency, when corrections made to the original article affect any data, figures, tables or texts, the retraction notice will display the original data alongside the corrected version. When a correction is not possible, all existing versions of the article will remain unchanged but will contain the bi-directional links, to and from, the published retraction notice.
    The notice of retraction is permanently linked to its corresponding retracted article and is freely available and accessible by all readers.
    Articles may be retracted by their Author(s), by the Journal Editors, or by the Publisher, i.e., Tech Science Press. In all instances, the retraction should indicate the reason for the action as well as the entity behind the decision. A retraction made without the unanimous agreement of the authors is feasible and indicated as such.

    Removal of Published Content

    Under special circumstances, TSP reserves the right to remove an article, book or other content from TSP’s website and submission system. Such action may be taken when:

    • There are evidence indicating that the published content is defamatory, infringes on intellectual property rights, privacy rights, other legal rights, or is plainly unlawful;

    • A court or government order requires removal of such content;

    • The content, if acted upon, would pose an immediate and serious risks to health. Removal may be temporary or permanent. A statement will be published explaining the decision behind the removal.

    Addressing Post-publication Issues

    TSP is fully committed to maintaining the integrity and completeness of the scientific record and recognizes its importance to researchers and the academic community at large. As such, TSP will thoroughly investigate concerns that are directly raised with us by authors and/or readers. Authors are strongly encouraged to address any raised issues. In the course of our investigation, we may request original raw data, and consult with experts and other scholars in the field. Depending on the seriousness of the issues, the following outcomes may ensue:

    • A manuscript still under consideration may be rejected and returned to the author.

    • A published online article, depending on the nature and severity of the issues, may result in a correction notice or a retraction notice.

    • Issues deemed to be serious may prompt TSP to inform the authors’ institution and related affiliations.

    Our actions are driven by our dedicated aim for transparent notification to our readers and unabated commitment to the integrity of the published record, and not by any motivation to sanction individuals or attribute responsibility to specific named individuals. We may refer readers to the institutional investigations’ reports if they are publicly available. While we are committed to addressing post-publications issues and correcting the record swiftly, investigations typically take some time to reach resolutions given the complexity of the discussions, the diligence in our process and the need to obtain original data and consult with experts. We will issue and regularly update relevant Editor’s Notes and/or Editor’s Expression of Concern as interim notifications to alert our readership of any of concerns with published material.

    15 Appeals and Complaints

    ONCOLOGIE is open for further discussion after either a publication or a rejection of a manuscript.

    Appeal against a Rejection

    Authors may appeal a rejection, or request further discussions or post-publication revisions, by contacting the Journal’s Editorial department. When making such an appeal or request, Authors must provide a detailed justification for their request, with a description of the situation, including point-by-point responses to the reviewers’ and/or editor’s comments. The Journal’s Managing Editor will then forward the manuscript and the related information (including the identities of the referees) to the Editor in charge (either one of the Editors-in-Chief or, an Editorial Board Member with any conflict of interest (COI), who will render a final and irreversible decision. Appeals will only be considered from the originally submitting Authors. All information will be kept confidential.

    As a general rule, an appeal to a Rejection Decision will only be considered if:

    • the authors can clearly and convincingly demonstrate that the final decision was based on an error made by a Referee or by the Editors during review

    • if important additional data can be provided

    • if a convincing case of bias in the process can be clearly demonstrated

    Authors who wish to appeal an Editorial decision should submit a formal letter of Appeal to the Journal by contacting the journal editorial office ( . Please include the manuscript number in the email subject line and on the appeal letter.

    If an appeal is successful, the Authors will be sent instructions on how to proceed. If an appeal merits further consideration, the Editor may decide to submit the Authors' response and the revised paper for further peer review.

    Complaint about Scientific Content

    Authors may contact the relevant Journal to file a complaint.
    The Editor-in-Chief or the Handling Editor will consider the Authors’ argument and the Reviewers’ reports, and will decide whether:

    • The decision to reject should stand

    • Another independent opinion is required

    • The appeal should be considered

    The complainant will be informed of the decision with an explanation when appropriate. Decisions on appeals are final and new submissions take priority over appeals.

    Complaint about Processes

    Authors may contact the Journal directly to raise a complaint concerning the process.
    The Editor-in-Chief together with the Handling Editor will investigate the matter. The complainant will be given appropriate feedback. Feedback is provided to relevant stakeholders to improve processes and procedures.

    Complaint about Publication Ethics

    Authors may send an email to concerning ethical issues or complaints.
    The Editor-in-Chief or the Handling Editor will diligently follow the guidelines published by the Committee on Publication Ethics in assessing the situation, and may resort to asking the Publisher via their in-house contact for advice on difficult or complicated cases. The Editor-in-Chief or the Handling Editor will  decide on a course of action and will provide relevant feedbacks to the complainant. If the complainant remains dissatisfied with the handling of the complaint, he/she may then submit the complaint to the Committee on Publication Ethics.

Share Link

WeChat scan